Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer

Exclusion Criteria

• •Life expectancy of at least 3 months as judged by the investigator
• •Medically unstable (e.g. acute cardiac or respiratory distress or hypotensive)
• •Exceeding the weight limit of the PET/CT bed (approximately 400 lbs.) or who cannot fit through the PET/CT bore (approximately 70 cm diameter)
• •Unmanageable claustrophobia
• •Prior failure of PSMA RLT
• •Prior hemi-body irradiation
• •Impaired organ function as evidenced by any of the following laboratory values:
• •* Absolute neutrophil count \< 1.5 x109/L
• •* Platelet count \< 75 x109/L
• •* Hemoglobin \< 85 g/L
• •* Albumin \< 2.5 g/dL (25 g/L)
• •* Total bilirubin \> 2 x ULN (unless in instances of Gilbert's disease)
• •* AST or ALT \> 2.5 x ULN (or \> 5.0 x ULN in the presence of liver metastases)